Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 177)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
2 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
3 |
|
Panobinostat |
Approved, Investigational |
Phase 4 |
|
404950-80-7 |
6918837 |
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
Faridak
FT-0083488
LBH 589
|
LBH589
LBH-589
LBH-589B
MolPort-005-933-338
nchembio.313-comp11
NVP-LBH589
NVP-LBH-589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
Panobinostatum
S1030_Selleck
ZINC22010649
|
|
4 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
5 |
|
Histone Deacetylase Inhibitors |
|
Phase 4 |
|
|
|
6 |
|
Aspirin |
Approved, Vet_approved |
Phase 3 |
|
50-78-2 |
2244 |
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoate
2-(ACETYLOXY)benzoIC ACID
2349-94-2
26914-13-6
2-Acetoxybenzenecarboxylate
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. empirin
A.S.A. Empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
acide 2-(acétyloxy)benzoïque
Acide acetylsalicylique
Acide acétylsalicylique
acido Acetilsalicilico
Acido acetilsalicilico
ácido acetilsalicílico
Acido O-acetil-benzoico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
AI3-02956
AIN
AKOS000118884
Aloxiprimum
ASA
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspirdrops
aspirin
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina
Aspirina 03
Aspirine
Aspir-Mox
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bialpirina
Bialpirinia
BIDD:GT0118
Bi-prin
BRN 0779271
Bufferin
C01405
Caprin
Cardioaspirin
Cardioaspirina
CCRIS 3243
Cemirit
CHEBI:15365
CHEMBL25
CID2244
Claradin
Clariprin
cMAP_000006
Colfarit
component of Midol
component of Synirin
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
Easprin
Easprin (TN)
ECM
Ecolen
Ecotrin
EINECS 200-064-1
Empirin
|
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EU-0100038
Extren
Globentyl
Globoid
Helicon
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
I14-7505
IDI1_000555
Idragin
Istopirin
Kapsazal
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
Levius
Lopac0_000038
Lopac-A-5376
LS-143
Magnecyl
Measurin
Medisyl
Micristin
MLS001055329
MLS001066332
MLS001336045
MLS001336046
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
nchem.859-comp6
NCI60_002222
Neuronika
NINDS_000555
Novid
NSC 27223
NSC27223
NSC406186
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-accetylsalicylic acid
O-Acetoxybenzoate
o-acetoxybenzoic acid
o-Acetoxybenzoic acid
O-Acetoxybenzoic acid
O-Acetylsalicylate
O-acetylsalicylic acid
O-Acetylsalicylic acid
o-carboxyphenyl acetate
o-Carboxyphenyl acetate
O-Carboxyphenyl acetate
O-Carboxyphenyl acetic acid
Persistin
Pharmacin
Pirseal
PL-2200
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
Salacetin
Salcetogen
Saletin
Salicylate acetate
Salicylic acid acetate
Salicylic acid acetic acid
Salicylic acid, acetate
Salospir
SMR000059138
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
SP 189
SPBio_001838
Spectrum_001245
SPECTRUM1500130
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
ST075414
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII=R16CO5Y76E
UNII-R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
Xaxa
XAXA
Yasta
Zorprin
ZORprin
|
|
7 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
8 |
|
Peginterferon alfa-2b |
Approved |
Phase 3 |
|
99210-65-8, 215647-85-1 |
|
Synonyms:
215647-85-1
D02748
Peginterferon alfa-2b
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
|
Peginterferon alfa-2b (INN)
PegIntron
PEG-Intron
Pegintron (TN)
Unitron PEG
|
|
9 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 3 |
|
198153-51-4 |
5360545 |
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
PEG-IFN alfa-2A
Peginterferon alfa-2a
PEG-Interferon alfa-2A
|
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Peginterferon alfa-2a (USAN/INN)
Pegylated Interfeaon alfa-2A
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
|
|
10 |
|
Anagrelide |
Approved |
Phase 3 |
|
68475-42-3 |
2182 |
Synonyms:
6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on
6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one
6,7-dichloro-1,5-dihydroimidazo(2,1-b)Quinazolin-2(3H)-one hydrochloride
6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one
6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
68475-42-3
AC1L1D3U
AC-3401
Agrelin
Agrylin
Anagrelida
Anagrelida [INN-Spanish]
anagrelide
Anagrelide
Anagrelide (INN/BAN)
Anagrelide [BAN:INN]
Anagrelide [INN:BAN]
Anagrelide hydrochloride
Anagrelidum
Anagrelidum [INN-Latin]
|
BIDD:GT0711
BL 416201
BL-4162a
BRN 0619582
C10H7Cl2N3O
CHEBI:142290
CHEMBL760
CID2182
D07455
HMS2089D21
HSDB 7325
I14-11970
imidazo(2,1-b)Quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride
LS-80464
MolPort-003-844-624
MolPort-005-934-314
NCGC00161408-01
UNII-K9X45X0051
ZINC03871541
|
|
11 |
|
Hydroxyurea |
Approved |
Phase 3 |
|
127-07-1 |
3657 |
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
12 |
|
Mercaptopurine |
Approved |
Phase 3 |
|
50-44-2 |
667490 |
Synonyms:
1,7-dihydro-6H-Purine-6-thione
1,7-Dihydro-6H-purine-6-thione
1,9-dihydro-6H-purine-6-thione
3,7-dihydropurine-6-thione
39454-94-9
3H-Purine-6-thiol
50-44-2
5759-99-9
5818-33-7
5818-60-0
6 Mercaptopurine
6 Mercaptopurine monohydrate
6 Mercaptopurine Monohydrate
6 MP
6 Thiohypoxanthine
6 Thiopurine
6112-76-1
6112-76-1 (monohydrate)
63810_FLUKA
6-Mercaptopurin
6-Mercaptopurine
6-Mercaptopurine monohydrate
6-MERCAPTOPURINE MONOHYDRATE
6-Merkaptopurin
6-Merkaptopurin [Czech]
6-MP
6-Purinethiol
6-Thiohypoxanthine
6-Thiopurine
6-Thioxopurine
7H-purine-6-thiol
7-Mercapto-1,3,4,6-tetrazaindene
9H-Purin-6-yl hydrosulfide
9H-Purine-6(1H)-thione
AC-11464
AC1LDI73
AG-670/31547064
AKOS000170222
AKOS000275858
Ambap50-44-2
BB_SC-0064
BSPBio_001981
BW 57 323H
C01756
C02380
C5H4N4S
CCRIS 2761
CHEBI:2208
CHEBI:50667
CHEMBL1425
CID667490
cMAP_000033
CPD000544948
D015122
D04931
DB01033
DivK1c_000493
EINECS 200-037-4
F3329-0452
FT-0083571
glaxo Wellcome brand OF 6 mercaptopurine
Glaxo Wellcome Brand of 6 Mercaptopurine
glaxo Wellcome brand OF 6-mercaptopurine
Glaxo Wellcome Brand of 6-Mercaptopurine
GlaxoSmithKline brand OF 6 mercaptopurine
GlaxoSmithKline Brand of 6 Mercaptopurine
GlaxoSmithKline brand OF 6-mercaptopurine
GlaxoSmithKline Brand of 6-Mercaptopurine
HMS1920L07
HMS2091B20
HMS501I15
HSDB 3235
I14-1716
IDI1_000493
Ismipur
KBio1_000493
KBio2_001401
KBio2_002363
KBio2_003969
KBio2_004931
KBio2_006537
KBio2_007499
KBio3_001481
|
KBio3_002842
KBioGR_001493
KBioGR_002363
KBioSS_001401
KBioSS_002366
Leukerin
Leukerin, 99% - Carc
Leupu rin
Leupurin
LS-141
M0063
Mercaleukim
Mercaleukin
Mercaptopurin
Mercaptopurin [German]
Mercaptopurina
Mercaptopurina [INN-Spanish]
Mercaptopurina wellcome
Mercaptopurina Wellcome
mercaptopurine
Mercaptopurine
Mercaptopurine (anhydrous)
Mercaptopurine (INN)
Mercaptopurine (VAN)
Mercaptopurine anhydrous
Mercaptopurine monohydrate
Mercaptopurine Monohydrate
Mercaptopurinum
Mercaptopurinum [INN-Latin]
Mercapurin
Merkaptopuryna
Merkaptopuryna [Polish]
Mern
MLS001066623
MLS001304020
MLS001304953
MolPort-001-783-696
MolPort-001-815-626
MolPort-003-846-751
MP
NCGC00094717-01
NCGC00094717-02
NCGC00094717-03
NCI60_041653
NCI-C04886
NCIMech_000025
NINDS_000493
NSC 755
NSC755
NSC-755
PM6
Puri nethol
Puri Nethol
Purimethol
purine antimetabolite: inhibits nucleic acid replication
Purine-6(1H)-thione
Purine-6-thiol
Purinethiol
Purinethol
Puri-nethol
Puri-Nethol
Purinethol (TN)
Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine
S1305_Selleck
SAM002589937
SMR000544948
SPBio_000219
Spectrum_000921
SPECTRUM1500387
Spectrum2_000060
Spectrum3_000491
Spectrum4_000857
Spectrum5_000950
STK727062
Thiopurine
U-4748
UNII-PKK6MUZ20G
Wellcome brand OF 6 mercaptopurine
Wellcome Brand of 6 Mercaptopurine
Wellcome brand OF 6-mercaptopurine
Wellcome Brand of 6-Mercaptopurine
WLN: T56 BM DN FN HNJ ISH
Xaluprine
|
|
13 |
|
Danazol |
Approved |
Phase 3 |
|
17230-88-5 |
28417 |
Synonyms:
(17a)-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
17 alpha-Pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol
17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
17230-88-5
17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
17a-Pregna-2,4-dien-20-yne-[2,3-D]isoxazole-17b-ol
17a-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-cyclopenta[7,8]phenanthro[3,2-D]isoxazol-1-ol
1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazole- pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol deriv.
AC1L1FAD
AC1Q282K
AC1Q29FD
AC-6836
Alphapharm brand OF danazol
Alphapharm Brand of Danazol
anatrol
Antigen brand OF danazol
Antigen Brand of Danazol
Azol
Bonzol
BPBio1_000100
BRD-K48970916-001-03-0
BSPBio_000090
CCRIS 6747
CHEBI:4315
CHEMBL1479
Chronogyn
CID28417
CPD000058321
Cyclomen
D00289
D003613
Danatrol
Danazant
danazol
Danazol
Danazol (JAN/USP/INN)
Danazol [USAN:BAN:INN:JAN]
Danazole
Danazol-ratiopharm
Danazolum
Danazolum [INN-Latin]
|
Danocrine
Danocrine (TN)
Danogen
Danokrin
Danol
Danoval
Danovaol
Danzol
DB01406
EINECS 241-270-1
HMS1568E12
HMS2090A22
Kendrick brand OF danazol
Kendrick Brand of Danazol
Ladogal
LS-118524
MLS001066617
MLS001306473
MolPort-002-513-504
NCGC00164400-01
NCGC00179665-01
Norciden
NSC 270916
NSC270916
Panacrine
Prestwick_150
Prestwick0_000105
Prestwick1_000105
Prestwick2_000105
Prestwick3_000105
ratiopharm Brand of Danazol
Ratiopharm brand OF danazol
SAM002564203
Sanofi brand OF danazol
Sanofi Brand of Danazol
Sanofi synthelabo brand OF danazol
Sanofi Synthelabo Brand of Danazol
Sanofi winthrop brand OF danazol
Sanofi Winthrop Brand of Danazol
SMR000058321
SPBio_002029
STOCK1N-23495
UNII-N29QWW3BUO
Win 17, 757
WIN 17,757
WIN 17757
WIN-17757
Winobanin
ZINC03881958
|
|
14 |
|
Melphalan |
Approved |
Phase 3 |
|
148-82-3 |
460612 4053 |
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
Medphalan
|
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
P-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
P-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
15 |
|
Cytarabine |
Approved, Experimental, Investigational |
Phase 3 |
|
147-94-4, 65-46-3 |
6253 |
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-beta-D-Ribofuranosylcytosine
1-β-D-arabinofuranosylcytosine
1β-D-ribofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-amino-1-b-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-b-D-Arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-amino-1-beta-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-beta-D-Arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1β-D-ribofuranosyl-2(1H)-pyrimidinone
4-amino-1-β-D-ribofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Arabinocytidine
Arabinofuranosylcytosine
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
Citidina
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytidin
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine riboside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
Zytidin
|
|
16 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
17 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
18 |
|
Analgesics |
|
Phase 3 |
|
|
|
19 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
20 |
|
Cyclooxygenase Inhibitors |
|
Phase 3 |
|
|
|
21 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
22 |
|
Antipyretics |
|
Phase 3 |
|
|
|
23 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
24 |
|
Mitogens |
|
Phase 3 |
|
|
|
25 |
|
Androgens |
|
Phase 3 |
|
|
|
26 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
27 |
|
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide |
|
Phase 3 |
|
|
|
28 |
|
Hormones |
|
Phase 3 |
|
|
|
29 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
30 |
|
Estrogen Antagonists |
|
Phase 3 |
|
|
|
31 |
|
Estrogen Receptor Antagonists |
|
Phase 3 |
|
|
|
32 |
|
Hepcidins |
|
Phase 3 |
|
|
|
33 |
|
Estrogens |
|
Phase 3 |
|
|
|
34 |
|
Citrate |
|
Phase 3 |
|
|
|
35 |
|
interferons |
|
Phase 3 |
|
|
|
36 |
|
Interferon-alpha |
|
Phase 3 |
|
|
|
37 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
38 |
|
Complement System Proteins |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
40 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
41 |
|
Interferon alpha-2 |
|
Phase 3 |
|
|
|
42 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
43 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
44 |
|
Janus Kinase Inhibitors |
|
Phase 3 |
|
|
|
45 |
|
glucocorticoids |
|
Phase 3 |
|
|
|
46 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 2 |
|
83-43-2 |
6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
47 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 2 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
48 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 2 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
49 |
|
Pomalidomide |
Approved |
Phase 2 |
|
19171-19-8 |
|
Synonyms:
|
50 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 2 |
|
52-21-1 |
|
Interventional clinical trials:
(show top 50)
(show all 180)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) |
Completed |
NCT01558739 |
Phase 4 |
INC424 |
2 |
A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients. |
Completed |
NCT00202644 |
Phase 4 |
Anagrelide;Hydroxyurea |
3 |
A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial |
Completed |
NCT00774566 |
Phase 4 |
|
4 |
A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment |
Recruiting |
NCT03232177 |
Phase 4 |
Anagre Cap. |
5 |
A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia |
Recruiting |
NCT04226950 |
Phase 4 |
Recombinant Interferon Alpha;Pegylated interferon alfa-2b |
6 |
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies |
Recruiting |
NCT02386800 |
Phase 4 |
ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation |
7 |
A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia |
Completed |
NCT01065038 |
Phase 3 |
Anagrelide;Hydroxyurea |
8 |
A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia |
Completed |
NCT01467661 |
Phase 3 |
SPD422 (anagrelide hydrochloride) |
9 |
A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment |
Completed |
NCT01214915 |
Phase 3 |
Anagrelide Hydrochloride |
10 |
A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia |
Completed |
NCT01230775 |
Phase 3 |
Anagrelide retard;Placebo |
11 |
A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis |
Completed |
NCT02087059 |
Phase 3 |
Ruxolitinib |
12 |
An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). |
Completed |
NCT01493414 |
Phase 3 |
INC424 |
13 |
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Completed |
NCT01969838 |
Phase 3 |
Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib |
14 |
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib |
Completed |
NCT02101268 |
Phase 3 |
Momelotinib;Best Available Therapy (BAT) |
15 |
A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0) |
Completed |
NCT02076815 |
Phase 3 |
Anagrelide retard;Thromboreductin |
16 |
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) |
Completed |
NCT01259856 |
Phase 3 |
PEGASYS;Hydroxyurea;Aspirin |
17 |
A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Recruiting |
NCT03755518 |
Phase 3 |
FEDRATINIB |
18 |
French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study |
Recruiting |
NCT02611973 |
Phase 3 |
Hydroxyurea treatment (HU) |
19 |
A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib |
Recruiting |
NCT03952039 |
Phase 3 |
FEDRATINIB;Best Available Therapy (BAT) |
20 |
A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis |
Recruiting |
NCT04173494 |
Phase 3 |
Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol |
21 |
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA) |
Recruiting |
NCT03165734 |
Phase 3 |
Pacritinib;Physician's Choice medications |
22 |
An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) |
Active, not recruiting |
NCT04209634 |
Phase 2, Phase 3 |
Pozelimab |
23 |
A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study |
Active, not recruiting |
NCT02962388 |
Phase 2, Phase 3 |
Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα |
24 |
Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. |
Active, not recruiting |
NCT01387763 |
Phase 3 |
PegIntron;Pegasys;PegIntron;Pegasys;Hydrea |
25 |
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia |
Not yet recruiting |
NCT04285086 |
Phase 3 |
|
26 |
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Terminated |
NCT01773187 |
Phase 3 |
Pacritinib;Best Available Therapy |
27 |
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Terminated |
NCT02055781 |
Phase 3 |
Pacritinib;Best Available Therapy |
28 |
A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. |
Unknown status |
NCT00866762 |
Phase 2 |
HDAC inhibitor (MK-0683) |
29 |
A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Unknown status |
NCT01298934 |
Phase 1, Phase 2 |
LBH589 |
30 |
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis |
Unknown status |
NCT00668421 |
Phase 1, Phase 2 |
CEP-701 (Lestaurtinib) |
31 |
A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia. |
Completed |
NCT00413634 |
Phase 2 |
anagrelide hydrochloride |
32 |
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation |
Completed |
NCT00586651 |
Phase 2 |
lestaurtinib |
33 |
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Completed |
NCT02515630 |
Phase 2 |
MMB |
34 |
A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN) |
Completed |
NCT02125318 |
Phase 2 |
Anagrelide CR |
35 |
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy |
Completed |
NCT01243073 |
Phase 2 |
Imetelstat |
36 |
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L |
Completed |
NCT01348490 |
Phase 2 |
Ruxolitinib |
37 |
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis |
Completed |
NCT00745550 |
Phase 1, Phase 2 |
SB1518 |
38 |
A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis |
Completed |
NCT01392443 |
Phase 2 |
Ruxolitinib |
39 |
Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia |
Completed |
NCT02124746 |
Phase 2 |
Momelotinib |
40 |
A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis |
Completed |
NCT01369498 |
Phase 2 |
Simtuzumab;Ruxolitinib |
41 |
A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis |
Completed |
NCT00039416 |
Phase 2 |
imatinib mesylate |
42 |
A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis |
Completed |
NCT01787552 |
Phase 1, Phase 2 |
LDE225;INC424 |
43 |
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET) |
Completed |
NCT00509899 |
Phase 1, Phase 2 |
Ruxolitinib |
44 |
Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage |
Completed |
NCT00949364 |
Phase 2 |
Pomalidomide |
45 |
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) |
Completed |
NCT00003239 |
Phase 2 |
Cytarabine;Omacetaxine Mepesuccinate |
46 |
A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM) |
Completed |
NCT00047190 |
Phase 2 |
tipifarnib |
47 |
A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases |
Completed |
NCT00606307 |
Phase 2 |
ITF2357 |
48 |
A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
Completed |
NCT01692366 |
Phase 2 |
SAR302503 |
49 |
A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia |
Completed |
NCT00227591 |
Phase 2 |
lenalidomide;prednisone |
50 |
A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. |
Completed |
NCT02966353 |
Phase 2 |
ruxolitinib |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Chlorambucil
|
Uracil Mustard
|
Cochrane evidence based reviews: thrombocytosis
|